Author Index

Adzick, N. S., 435, 448, 462, 524, 535
Allan, W. C., 212
Anthony, J., 65
Aranda, J. V., 211, 250
Arceci, R. J., 274, 319
Armand, M., 242

Baylis, C., 2
Beaudoin, M. C., 250
Bedford, H., 218
Belfort, M. A., 65
Bennett, M. J., 100
Bianchi, D. W., 393
Bonafé, L., 162
Bove, K. E., 310
Brown, J., 226
Burlina, A. B., 162

Canick, J. A., 359
Ceriani, R. L., 242
Crombleholme, T. M., 448, 474, 496

Dekker, G. A., 24
De Leeuw, R., 234
Delisle, M.-F., 414
Devine, P. C., 382
De Vivo, D. C., 113
DiMauro, S., 113

Evans, D. J., 226

Flake, A. W., 448, 515, 524

Gaiser, R. R., 507
Gallagher, P. G., 261, 341
Garfield, R. E., 34
Geyer, J. R., 286
Gibson, B., 100
Giordano, G., 204
Glibetic, M., 250
Gosche, J. R., 341

Hamosh, M., 242
Hamosh, P., 242
Harty, M. P., 437
Harvey, D., 218
Hauck, W., 250
Henderson, T. R., 242
Hirano, M., 113
Holt, D. E., 218
Howell, L. J., 535
Huang, F., 319
Hubbard, A. M., 437
Hudgins, R. J., 286
Hyland, K., 194

Ibdah, J., 100

Jenkins, T. M., 403
Johnson, M. P., 448, 484

Katz, K. H., 212
Kellner, L. H., 359
Kitano, Y., 448
Kiwan, R., 242
Kollé, L. A. A., 234
Kurth, C. D., 507

Lampkin, B. C., 261, 274
Levene, M. I., 226
Liechty, K. W., 496
Longo, N., 152
Losonczy, G., 2
Lukens, J. N., 263

Mahoney, M. J., 341
Makuch, R. W., 212
Malone, F. D., 357, 369, 382
Mason, S., 226
Mattar, F., 58
Mazewski, C. M., 286
Mehta, N. R., 242
Ment, L. R., 212
Miller, M. E., 174
Milner, R., 474
Miodovnik, M., 45
Morgan, T., 14
Mueller, B. U., 332
Mulliken, J. B., 332
Myatt, L., 45

Noya, F. J. D., 250

O'Brien, L. K., 100
Olutoye, O. O., 462
Ozand, P. T., 183

Palumbo, J. S., 299
Pertl, B., 393
Peterson, J. A., 242
Podjarny, E., 2

Rahbeeni, Z., 183
Rashed, M. S., 183
Raymond, K., 204
Reece, E. A., 424
Reisner, A., 286
Ricard, G., 250
Rinaldo, P., 99, 100, 204

Saade, G. R., 1, 34, 65
Samlalsingh-Parker, J., 250
Sande, J. E., 274
Scaglia, F., 152
Scallan, C. D., 242
Schneider, K. C., 212
Scott, D. T., 212
Shaaban, A. F., 515
Sibai, B. M., 24, 58
Sims, H. F., 100
States, L. J., 437
Stewart, T. L., 369
Strauss, A. W., 100
Sue, C. M., 113

Tein, I., 125
Tiozzo, C., 204

Van der Heide, A., 234
Van der Maas, P. J., 234
Van der Wal, G., 234
Van Hook, J. W., 79
Vedernikov, Y., 34
Vohr, B., 212

Walsh, D. S., 484
Wapner, R. J., 403
Ward, K., 14
Wilson, R. D., 414
Witlin, A. G., 91

Yang, E. Y., 524
Yoon, H.-R., 204
Yu, C., 204

Zacchello, F., 162
Zhao, Y., 100
Zwerdling, T., 299

Subject Index

AAV vectors in fetal gene therapy, 525-526
Abdominal mass
  fetal ultrafast MRI of, 444
  in neonatal neuroblastoma, 265
Abdominal ultrafast magnetic resonance imaging (MRI), fetal, 444-446
Ablation
  fetoscopic cystoscopic, of posterior urethral valves in obstructive uropathy, 491
  fetoscopic laser, for TTTS, 479-481
Abnormal nuchal translucency, defined, 374-375
Accuracy of first trimester amniocentesis results, 417-418
N-Acetylglutamic acid synthetase (NAGS) deficiency, neonatal, neurological distress and, 164-165
Acid maltase deficiency (AMD), neonatal metabolic myopathies and, 126-128
Acidemia, neonatal, neurological distress and
  isovaleric, 170
  methylmalonic, 169, 170
  propionic, 169
Acidopathies, *see* Neonatal amino acid and organic acid disorders
Aciduria, mevalonic, neurological distress and, 171
Acute fatty liver of pregnancy (AFLP), 105-109
  described, 106-107
  and fetal LCHAD deficiency, 107-109
Acute lymphoblastic leukemia (ALL), neonatal, 278-279
Acute myelogenous leukemia (AML), neonatal, 277, 278
Adaptation, *see* Fasting adaptation, FAO disorders and
Adenomatoid malformations, congenital cystic, *see* Congenital cystic adenomatoid malformations, open fetal surgery for
Adenoviral vectors in fetal gene therapy, 525
Adriamycin nephropathy model of preeclampsia, 6-7
Advantages of fetal gene therapy, 524-525
AFLP, *see* Acute fatty liver of pregnancy
AGT (angiotensinogen) gene, mutation of, and preeclampsia, 18-20, 52
Airway obstruction, fetal surgery for, 496-506
  with EXIT procedure, 499-504
  obstruction due to extrinsic compression, 497-498
  obstruction due to intrinsic airway defects, 495-496
  ultrasound diagnosis of, 499
ALL (acute lymphoblastic leukemia) neonatal, 278-279
Alpha (α)-ketoglutarate dehydrogenase deficiency, 115, 117
AMD (acid maltase deficiency), neonatal metabolic myopathies and, 126-128
Amino acid disorders, *see* Neonatal amino acid and organic acid disorders
AML (acute myelogenous leukemia), neonatal, 277, 278
Amniocentesis, first trimester (early amniocentesis), 414-423
  accuracy of results of, 417-418
  complications of, 411, 418-421
  defined, 415
  embryology and, 415
  first trimester CVS compared with, 411
  technique of, 415-417
Amniotic fluid leakage, as early amniocentesis complication, 419
Anesthesia for fetal surgery, 507-514
  fetal considerations in, 510-512
  maternal considerations in, *see* Maternal considerations in anesthesia for fetal surgery
Aneuploidy, *see* Nuchal translucency sonography, first trimester, screening for aneuploidy with; Serum biochemical markers, first trimester screening for aneuploidy with *and specific conditions*
Angioblastoma (tufted angioma; TA), neonatal, 336
Angioma, tufted, neonatal, 336
Angiomatous hamartoma, eccrine, neonatal, 337
Angiosarcoma, neonatal, 337
Angiotensinogen (*AGT*) gene, mutation of, and preeclampsia, 18-20, 52
Anomalies, *see* Malformations and anomalies
Antenatal conditions and interventions, *see entries beginning with terms*: Fetal, Intrauterine, In utero
Antibodies in detection of fetal cells in maternal blood, 396
Antihypertensives in preeclampsia
  antihypertensive effects of $MgSO_4$ on eclamptic seizures, 68-69
  preeclampsia prevention with, 62
Antimicrobial, antiprotozoan, and antiviral function of MFG, *see* Human milk fat globule, protective function of
Antithrombotic agents, prevention of preeclampsia with, 58-60
Arginase deficiency, neonatal, neurological distress and, 166-167
Argininosuccinase deficiency, neonatal screening for, with electrospray MS/MS, 186
Argininosuccinic acid lyase deficiency, neonatal, neurological distress and, 166
Argininosuccinic acid synthetase deficiency, neonatal, neurological distress and, 166
Aromatic L-amino acid decarboxylase deficiency
  diagnosis and therapy of, 200
  and monoamine biosynthesis, 197
Arterial perfusion sequence, twin reversed, fetoscopy for, 476-478
Asphyxia, *see* Secondary neuronal injury, severe birth asphyxia due to
Aspirin, low-dose, preeclampsia prevention with, 59-60
Assessment, *see* Evaluation
Associated conditions, *see* Syndromic associations *and specific conditions*
Automated electrospray tandem mass spectrometry (MS/MS) for inborn errors of metabolism, sample throughput and, 185-186
Autopsy in case of sudden and unexpected death due to pediatric FAO disorders, specimen collection for, 207

Autosomal dominantly inherited guanosine triphosphate (GTP) cyclohydrolase deficiency, 196

Bacterial meningitis, *see* Neonatal bacterial meningitis
Beckwith-Wiedemann syndrome (BWS) with WT, 315
Benign cephalic histiocytosis in infancy, 328
Benign vascular tumors, *see* Vascular tumors in infancy
Beta-human chorionic gonadotropin, *see entries beginning with*: Free β-hCG
Beta-hydroxy-γ-trimethylammonium butyrate, *see* Carnitine in neonatal metabolic myopathies due to FAO disorders
Biochemical markers
  neuronal differentiation, in neonatal neuroblastoma, 264
  see also Serum biochemical markers, first trimester screening with
Biochemical mediators of inflammation triggered by neonatal GBS meningitis, 251-252
Biochemistry
  of AMD, 126
  of branching enzyme deficiency, 133
  of debrancher deficiency, 131
  of FAO disorders, 102-103, 134-139
  of inflammation triggered by neonatal GBS meningitis, 255-256
  of PBK deficiency, 128-129
  of PFK deficiency, 131
  of PGK deficiency, 132
  of phosphorylase deficiency, 129-130 *see also entries beginning with term*: Biochemical
Biology
  biological basis of neonatal neuroblastoma, 263-264
  biological plausibility of neuroprotective therapy after severe birth asphyxia, 228
  of fetal cells in maternal blood at different gestational ages, 394-395
  of free β-hCG and PAPP-A, 364-365
  of histiocytoses of infancy, 319-321
  see also Genetics
Biopsy, *see* Muscle biopsy
Birth asphyxia, *see* Secondary neuronal injury, severe birth asphyxia due to
Birthmarks, *see* Vascular tumors of infancy
Bleeding, *see* Hemorrhages
Blood circulation, *see* Fetal cell(s) in maternal circulation, first trimester screening for; Uteroplacental circulation
Blood flow velocity, uteroplacental, in preeclampsia, Doppler ultrasound measurement of, 53-54
Blood pressure, *see* Hypertension in preeclampsia
Blood sampling, fetal, with embryofetoscopy, 428-429
Bone disease, *see* Temporary brittle bone disease, perinatal
Brain, *see* Brain injury, and neonatal GBS meningitis; Brain tumors, neonatal *and entries beginning with terms*: Cerebral, Cerebrovascular
Brain injury, and neonatal GBS meningitis
  pathophysiological consequences of inflammation leading to, 251
  see also Group B *Streptococcus* meningitis, neonatal
Brain tumors, neonatal, 286-298
  case presentations, 286-287
  clinical features of, 291-293
  congenital and neonatal defined, 288
  diagnosis of, 293-294
  discussion on, 295-296
  epidemiology of, 288-290
  prognosis of, 295
  recommendations on, 296
  therapy and management of, 294-295
Branching enzyme deficiency, neonatal metabolic myopathies and, 128, 132-133
Brittle bone disease, *see* Temporary brittle bone disease, perinatal
BWS (Beckwith-Wiedemann syndrome) with WT, 315

Calcium
  secondary neuronal injury due to, 226-227
  see also Calcium antagonists; Calcium in preeclampsia
Calcium antagonists, prevention of eclamptic seizures with, 69-72
Calcium in preeclampsia
  calcium deficiency model of preeclampsia, 9
  supplementation with, in preeclampsia prevention, 60, 61
Cancer, *see* Neonatal tumors *and specific cancers*
Candidate diseases for fetal HSCTx, 516-520
  diseases with minimal engraftment requirement for amelioration as, 520
  diseases with selective advantage for normal cells as, 518-519
  hemoglobinopathies as, 519-520
Carbamyl phosphate synthetase (CPS) deficiency, neonatal, neurological distress and, 165
Carbohydrates in high-carbohydrate, low-fat diet, therapy of FAO disorders with, 142
Carcinoma, *see* Neonatal tumors *and specific carcinomas*
Cardiac defects, first trimester nuchal translucency sonography in detection of, 384-386
Cardiomyopathy, neonatal histocytoid, and Complex III deficiency, 118
Cardiovascular system
  effects of bacterial meningitis on cerebral microvessels, *see* Neonatal bacterial meningitis
  maternal, anesthesia for fetal surgery and, 507-508
  see also entries beginning with terms: Cerebrovascular, Vascular *element*: Card- *and specific arteries*
Carnitine, *see* Carnitine in neonatal metabolic myopathies due to FAO disorders; Primary and secondary neonatal carnitine deficiency
Carnitine (β-hydroxy-γ-trimethylammonium butyrate) in neonatal metabolic myopathies due to FAO disorders, 139-143

altered tissue and plasma, 134-135
laboratory data on, 137
as therapy, 141-143
total, 139
uptake of, 140-141
Catabolism
defects of monoamine, 198
of serotonin and catecholamines, 194-195
Catecholamines, synthesis and catabolism of, monoamine neurotransmission disorders and, 194-195
Categories of disabilities due to bacterial meningitis, 223, 224
Catheter, pulmonary artery, indications for, in severe preeclampsia, 82-84
CCAMs, *see* Congenital cystic adenomatoid malformations, open fetal surgery for
CDH, *see* Congenital diaphragmatic hernia, open fetal surgery for
Cell therapy, fetal, embryofetoscopy in, 429-430
Center for Fetal Diagnosis and Treatment (CFDT), 535-540
communication in, 539
cost of fetal therapy and, 539
discharge planning by, 538
follow-up program of, 538-539
multidisciplinary team of specialists in, 536
obstetric unit of, 537-538
operating room and maternal-fetal unit of, 538
patient evaluation by, 537
patient referral program of, 536-537
Central nervous system
fetal ultrafast MRI of anomalies of, 438-441
see also entries beginning with terms: Brain, Cerebral, Cerebrovascular
Cephalic histiocytosis, benign, of infancy, 328
Cerebral autoregulation, and choice of agents to prevent eclamptic seizures, 75
Cerebral edema in severe preeclampsia, management of, 86-87
Cerebral microvessels, *see* Neonatal bacterial meningitis
Cerebral perfusion pressure (CPP), prevention of eclamptic seizures and, 73-75
choice of prophylactic agents for, cerebral autoregulation and, 75
Doppler ultrasound of, 73-74
before and after $MgSO_4$ or nimodipine therapy, 74-75
Cerebrovascular accident (CVA) in severe preeclampsia, management of, 86-87
Cervical lymphangioma, fetal, airway obstruction due to, 497-498
Cervical mass in neonatal neuroblastoma, 266
Cervical teratoma, fetal, airway obstruction due to, 498
CF (cystic fibrosis), lung-directed fetal gene therapy for, 527
CFDT, *see* Center for Fetal Diagnosis and Treatment
CHAOS (congenital high airway obstruction syndrome), *see* Airway obstruction, fetal surgery for
Chemistry
of free β-hCG and PAPP-A, 364-365
see also Biochemistry
Chest anomalies, fetal ultrafast MRI of, 442-444
Child abuse, fractures and, 178-181
Chorionic gonadotropin, human, free β-hCG compared with, 362-363; *see also entries beginning with*: Free β-hCG
Chorionic villus sampling (CVS), first trimester, 403-413
complications of, *see* Complication(s), first trimester CVS
early amniocentesis compared with, 411
indications for, 405-406
in multiple gestation detection, 410-411
the procedure, 403
results of, analyzed, 406-408
timing and techniques of, 403-405
Chromosomal constitution of karyotyped cystic hygroma fetuses, 345
Chronic hyperinsulinemia in hypertension model of preeclampsia, 7-9
Chronic nitric oxide synthase (NOS) inhibition model of preeclampsia, 5-6
Circulation, *see* Fetal cell(s) in maternal circulation, first trimester screening for; Uteroplacental circulation
Classification
of histiocytoses of infancy, 321-322
histopathologic, of neonatal neuroblastoma, 264
of mitochondrial metabolism disorders, 115
of neonatal vascular malformations, 334, 337
of neonatal vascular tumors, 332, 333
Clinical applications of first trimester screening with embryofetoscopy, 428-431
for fetal cells in maternal blood, 397-398
for fetal structural abnormalities with nuchal translucency sonography, 389-390
Clinical experience
early, with fetal surgery of MMC, 469-571
with fetal HSCTx, 516, 517
with neuroprotective therapy after severe birth asphyxia, 230-231
Clinical features and presentation
of AMD, 126
of debrancher deficiency, 130
of FAO disorders, 101-102
of fetal and neonatal cystic hygroma, 346-349
of HLH, 326
of LCH, 323-324
of monoamine neurotransmission disorders, 195-197
of myopathies due to FAO disorders, 134-139
of neonatal brain tumors, 291-293
of neonatal leukemia, 276-277
of neonatal neuroblastoma, 265-267
of PBK deficiency, 128
of PFK deficiency, 131
of PGK and branching enzyme deficiency, 132
of phosphorylase deficiency, 129
of temporary brittle bone disease, 176
see also specific conditions

Clinical heterogeneity of neonatal neuroblastoma, 263-264
Clinical observations on LCHAD deficiency, 107
c-myc-related oncogene amplification in neonatal neuroblastoma, 264
Coagulation, fibrinolytic systems and, in preeclampsia, 49-50
Collection of second samples for neonatal electrospray MS/MS of inborn errors of metabolism prior to discharge, 189-190
Collective network in neuroprotective therapy after severe birth asphyxia, 231
Common features shared by FAO disorders, 135-137
Common soft tissue sarcomas of infancy, 300-302
Communication in CFDT, 539
Complete trifunctional protein (TFP) deficiency, 105
Complex I (NADH-ubiquinone reductase) deficiency, and mitochondrial disorders of respiratory chain, 115, 118
Complex III deficiency, and mitochondrial disorders of respiratory chain, 115, 118
Complex IV (cytochrome *c* oxidase) deficiency, and mitochondrial disorders of respiratory chain, 115, 118-119
Complicated preeclampsia, *see* Severe preeclampsia, management of
Complication(s)
of first trimester amniocentesis, 411, 418-421
of first trimester CVS, *see* Complication(s), first trimester CVS
obstetrical, *see* Complication(s), obstetrical
of open fetal surgery for life-threatening malformations, 449-450
potential aneuploidy, first trimester screening with serum biological markers for, 364
of severe preeclampsia, management of, 86-88
see also Monochorionic twin pregnancy, fetoscopy for complications of *and specific conditions*
Complication(s), first trimester CVS, 408-411
fetal loss as, 408-409, 411
Complication(s), obstetrical
first trimester free β-hCG screening for potential, 364
LCHAD-deficient fetuses and, 108-109
Compound heterozygotes with guanosine triphosphate cyclohydrolase deficiency, 196-197
Compression, extrinsic, fetal airway obstruction due to, 497-498
Confined placental mosaicism (CPM), first trimester CVS in detection of, 407-408
Confirmation of diagnosis
with electrospray MS/MS, 187-189
embryofetoscopic, of structural anomalies diagnosed with nuchal translucency sonography, 428
Congenital brain tumor, defined, 288
Congenital cystic adenomatoid malformations (CCAMs), open fetal surgery for, 450-453
natural history of CCAMs, 450-451
pathophysiology of, 451
the procedure, 452-453
ultrasound diagnosis of, 451-452
Congenital diaphragmatic hernia (CDH), open fetal surgery for, 454-457
natural history of, 454
pathophysiology of, 454-455
the procedure, 455-457
Congenital hemangiopericytoma/infantile myofibromatosis, 337
Congenital high airway obstruction syndrome, *see* Airway obstruction, fetal surgery for
Congenital leukemia, *see* Leukemia, neonatal
Congenital Wilms' tumor (WT), 313
Corn starch, uncooked, as therapy of FAO disorders, 142
Cost of fetal therapy, CFDT and, 539
Counseling, *see* Genetic counseling
Course
of fetal and neonatal cystic hygroma, 346-349
see also specific conditions
COX (cyclooxygenase), *see* Inflammatory cascade triggered by neonatal GBS meningitis, deregulation of COX and NOS gene expression in
CPM (confined placental mosaicism), first trimester CVS in detection of, 407-408
CPP, *see* Cerebral perfusion pressure, prevention of eclamptic seizures and
CPS (carbamyl phosphate synthetase) deficiency, neonatal, neurological distress and, 165
Critical closing pressure, defined, 73
CVA (cerebrovascular accident) in severe preeclampsia, management of, 86-87
CVS, *see* Chorionic villus sampling, first trimester
Cyclohydrolase deficiency, *see* Guanosine triphosphate cyclohydrolase deficiency
Cyclooxygenase, *see* Inflammatory cascade triggered by neonatal GBS meningitis, deregulation of COX and NOS gene expression in
Cystic adenomatoid malformations, congenital, *see* Congenital cystic adenomatoid malformations, open fetal surgery for
Cystic fibrosis (CF), lung-directed fetal gene therapy for, 527
Cystic hygroma, fetal and neonatal, 341-356
embryology of, 341-342
genetic counseling for, 353
genetics of, 342-345
pathology of, 345-346
presentation and course of, 346-349
therapy and management of, *see* Therapy and management of fetal and neonatal cystic hygroma
Cystoscopic ablation, fetoscopic, of posterior urethral valves in obstructive uropathy, 491
Cytochrome *c* oxidase (complex IV) deficiency, and mitochondrial disorders of respiratory chain, 118
Cytogenetic abnormalities in neonatal neuroblastoma, 264
Cytokines in preeclampsia, 28, 51-52

DDS (Denys-Drash syndrome) with WT, 314-315
Death
  sudden and unexpected, postmortem pediatric diagnosis of FAO disorders in, 204-210
  see also End-of-life decisions for neonates, study on; Mortality
Death certificates, incidence of end-of-life decision as noted in, 236
Debrancher deficiency, neonatal metabolic myopathies and, 128, 130-131
Decompensation, *see* Metabolic decompensation
Deliberate ending-of-life of neonates, decision on, 240
Delivery of severely preeclamptic patients, 81-82
Denys-Drash syndrome (DDS) with WT, 314-315
Deoxyribonucleic acid, *see* DNA
Detection, *see* Diagnosis
Development, *see* Growth and development
Diagnosis
  and end-of-life decisions, 237
  fetal, *see* Center for Fetal Diagnosis and Treatment; Fetal ultrasound; First trimester screening and diagnosis; Ultrafast magnetic resonance imaging, fetal anomalies diagnosed with *and specific conditions*
  hemangioma, 334-335
  of HLH, 326-327
  of neonatal bacterial meningitis, 219
  of neonatal brain tumors, 293-294
  of neonatal neuroblastoma, 268-270
  see also Diagnosis of inborn errors of metabolism in neonates; Evaluation; Screening *and specific conditions*
Diagnosis of inborn errors of metabolism in neonates
  amino and organic acidopathies, 162-164, 170
  carnitine deficiency, 157-159
  differential, *see* Differential diagnosis of inborn errors of metabolism
  monoamine neurotransmission disorders, 198-201
  see also Diagnosis of neonatal FAO disorders; Electrospray tandem mass spectrometry, neonatal screening with, for inborn errors of metabolism
Diagnosis of neonatal FAO disorders
  and of myopathies due to FAO disorders, 139-141
  postmortem, in sudden and unexpected death, 204-210
Diaphragmatic hernia
  first trimester nuchal translucency sonography in detection of, 385-386
  see also Congenital diaphragmatic hernia, open fetal surgery for
Dicarboxylic acids in neonatal metabolic myopathies due to FAO disorders, laboratory data on, 137-139
Dietary sources of carnitine, 152-155
Dietary therapy
  of carnitine deficiency, 156
  of FAO disorders, 142
  in prevention of preeclampsia, 60-62
Differential characteristics of histiocytes, 321
Differential diagnosis
  of extrinsic fetal airway obstruction, 497
  of fetal and neonatal cystic hygroma, 347-349
  of neonatal leukemia, 280-282
  of soft tissue sarcomas of infancy, 300
  see also Differential diagnosis of inborn errors of metabolism
Differential diagnosis of inborn errors of metabolism
  between child abuse and temporary brittle bone disease, 178-181
  of methylmalonic acidemia, 169, 170
Differentiation markers, neuronal, in neonatal neuroblastoma, 264
Dihydrolipoyl dehydrogenase deficiency, 115, 117
Dihydropteridine reductase deficiency without hyperphenylalaninemia, 197
Discharge
  planning of, by CFDT, 538
  second sample collection for neonatal electrospray MS/MS of inborn errors of metabolism prior to, 189-190
Discordance for anomalies in monochorionic twins, fetoscopy for, 475-476
Distress, neurological, *see* Neurological distress, neonatal, amino and organic acidopathies and
Diuretics, prevention of preeclampsia with, 62
DNA (deoxyribonucleic acid)
  fetal, in maternal blood, 398
  see also DNA defects of respiratory chain
DNA (deoxyribonucleic acid) defects of respiratory chain, 117-121
  mitochondrial, 119-121
  nuclear, 117-118
Doctor-patient relationship, end-of-life decisions for neonates and, 240-241
Dopamine β-hydroxylase deficiency
  diagnosis and therapy of, 200
  and monoamine biosynthesis, 197-198
Doppler ultrasound of preeclampsia
  of CPP, 73-74
  of uteroplacental blood flow velocity, 53-54
Down's syndrome (trisomy 21)
  differential diagnosis between neonatal acute leukemia and, 281-282
  see also Down's syndrome, first trimester screening for
Down's syndrome (trisomy 21), first trimester screening for
  with detection of fetal cells in maternal circulation, 397-398
  see also Down's syndrome, first trimester screening for, with serum biochemical markers; Nuchal translucency sonography, first trimester, screening for aneuploidy with
Down's syndrome (trisomy 21), first trimester screening for, with serum biochemical markers
  and effectiveness of second trimester biochemical markers in first trimester, 360

see also Free β-hCG in first trimester screening for Down's syndrome; PAPP-A in first trimester screening for Down's syndrome

E474Q mutation in LCHAD and TFP deficiencies, FAO and, 103-105
Early amniocentesis, *see* Amniocentesis, first trimester
Early-onset intraventricular hemorrhage (IVH) in preterm infants, incidence of neurodevelopmental handicaps with, 212-217
Eccrine angiomatous hamartoma ("eccrine nevus"), neonatal, 337
Echography, *see* Doppler ultrasound of preeclampsia; Fetal ultrasound *entries beginning with terms*: Nuchal translucency sonography *and specific conditions*
Eclamptic seizures, prevention of, 65-78
  with calcium antagonists, 69-72
  CPP and, *see* Cerebral perfusion pressure, prevention of eclamptic seizures and
  and etiology of seizures, 65-66
  with magnesium sulfate, *see* Magnesium sulfate in prevention of eclamptic seizures
Edema, cerebral, in severe preeclampsia, management of, 86-87
Edwards syndrome (trisomy 18), first trimester screening for, with serum biochemical markers, 364
Elastase in preeclampsia, 28-29
Electrospray tandem mass spectrometry (MS/MS), neonatal screening with, for inborn errors of metabolism, 183-193
  for argininosuccinase deficiency, 186
  automated, sample throughput and, 185-186
  metabolic profiling with, 184-185
  prospective pilot study with, 187
  second samples and, *see* Second samples for neonatal electrospray MS/MS of inborn errors of metabolism
  as tool for diagnosis confirmation and treatment follow-up, 187-189
Elevated liver enzymes, *see* HELLP
Embryofetoscopy, 424-433
  clinical applications of, 428-431
  endoscopy and, 424-425
  ethics of, 431
  in human embryology study, 427-428
  technique of, 425-425
Embryology
  embryofetoscopy in study of, 427-428
  of fetal and neonatal cystic hygroma, 341-342
  first trimester amniocentesis and, 415
  of MMC, 462-463
Embryonic development, embryofetoscopic study of, 427-428
End-of-life decisions for neonates, study on, 234-241
  conclusions of, 239
  death certificate study, 236
  discussion on, 239-241
  interview results, 236-239
  study methods, 235-236
Endoscopy
  background on, 424-425
  see also Embryofetoscopy; Monochorionic twin pregnancy, fetoscopy for complications of
Endothelium in preeclampsia
  dysfunction of, 50-51
  and vascular reactivity, 35-36
  see also Nitric oxide in preeclampsia
Endotoxin model of preeclampsia, 9
Engraftment requirement for amelioration, diseases with minimal, as candidates for HSCTx, 520
Entry point for neuroprotective therapy after severe birth asphyxia, 229-230
Enzymes
  assays of, in diagnosis of FAO disorders, 140
  deficiency in branching, neonatal metabolic myopathies and, 128, 132-133
  in detection of fetal cells in maternal blood, 396
  see also specific enzymes
Epidemiology
  of neonatal brain tumors, 288-290
  see also Incidence; Prevalence of fetal structural abnormalities *and specific conditions*
Errors of metabolism *see* Inborn errors of metabolism, neonatal
ES (Ewing sarcoma) of infancy, 304-306
Ethics
  of embryofetoscopy, 431
  of fetal gene therapy, 532-533
  see also End-of-life decisions for neonates, study on
Etiology
  of neonatal leukemia, 275
  see also Etiology of preeclampsia *and specific conditions*
Etiology of preeclampsia, 26-30, 47-48
  of eclamptic seizures, 65-66
  as genetic disease, 29-30; *see also* Genetics of preeclampsia
  immune maladaptation hypothesis of, 27-29
  placental ischemia hypothesis of, 15, 27
  renal, 17, 54
Evaluation
  of families with maternal liver disease, 110-111
  neuroblastoma, *see* High-risk neuroblastoma; Intermediate-risk neuroblastoma; Low-risk neuroblastoma
  see also Diagnosis; Patient evaluation
Ewing sarcoma (ES) of infancy, 304-306
Examination, physical, for neonatal metabolic myopathies due to FAO disorders, 139
EXIT procedure for fetal airway obstruction, 499-504
Expectant management of severe preeclampsia, 79-81
Experimental support
  for fetal HSCTx, 515-516
  for fetal surgery of obstructive uropathy, 486
Extremities, paresis of upper, and neonatal neuroblastoma 265-266
Extrinsic compression, fetal airway obstruction due to, 497-498

Factor V Leiden, mutation of, and preeclampsia, 20-21, 52
False-negative and false-positive results with electrospray MS/MS of inborn errors of metabolism, 190-191
Familial Wilms' tumor (FWT), 314
Families
  with maternal liver disease of pregnancy, evaluation of, 110-111
  see also Familial Wilms' tumor; Parents, end-of-life decisions for neonates and; Siblings
FAO, *see* Fatty acid oxidation
Fasting adaptation, FAO disorders and, 133-134
  studies of, in diagnosis of FAO disorders, 139-140
Fat
  in high-carbohydrate, low-fat diet, therapy of FAO disorders with, 142
  see also Oil
Fatty acid oxidation (FAO)
  and carnitine deficiency, 155-157
  FAO-dependent tissues involved in FAO disorders, 134
  mammalian, 100-101
  see also Fatty acid oxidation disorders, neonatal
Fatty acid β-oxidation (FAO)
  biochemistry of, 101
  and carnitine deficiency, 157
Fatty acid oxidation (FAO) disorders, neonatal, 101-105
  biochemistry of, 101-103
  clinical manifestations of, 101-102
  LCHAD and TFP deficiencies and, 103-105
  postmortem diagnosis of, in sudden and unexpected death, 204-210
  see also Fatty acid oxidation disorders, neonatal metabolic myopathies due to
Fatty acid oxidation (FAO) disorders, neonatal metabolic myopathies due to, 133-151
  carnitine in, *see* Carnitine in neonatal metabolic myopathies due to FAO disorders
  clinical and biochemical features of, 134-139
  diagnosis of, 139-141
  fasting adaptation and, 133-134
  historical background of, 133
  presymptomatic screening of siblings for, 143
  treatment of, 141-143
Fatty liver of pregnancy, *see* Acute fatty liver of pregnancy
Fetal airway obstruction, *see* Airway obstruction, fetal surgery for
Fetal anomalies
  monochorionic twins discordant for, fetoscopy for, 475-476
  see also Fetal diagnosis; Fetal surgery *and specific anomalies*
Fetal blood sampling with embryofetoscopy, 428-429
Fetal cell(s) in maternal circulation, first trimester screening for, 393-402
  clinical applications of, 397-398
  fetal cell microchimerism and, 398-399
  fetal cell recognition and genetic analysis, 396-397
  fetal DNA and, 398
  selection of target cells, 393-395
  strategies for separation of, 395-396
Fetal cell therapy, embryofetoscopy in, 429-430
Fetal considerations in anesthesia for fetal surgery, 510-512
Fetal cystic hygroma, *see* Cystic hygroma, fetal and neonatal
Fetal diagnosis, *see* Center for Fetal Diagnosis and Treatment; Fetal ultrasound; First trimester screening and diagnosis; Ultrafast magnetic resonance imaging, fetal anomalies diagnosed with *and specific conditions*
Fetal DNA (deoxyribonucleic acid) in maternal blood, 398
Fetal gene therapy, 524-534
  advantages of, 524-525
  embryofetoscopy in, 429-430
  ethics of, 532-533
  HSC-directed, 532
  liver-directed, *see* Liver-directed fetal gene therapy
  lung-directed, *see* Lung-directed fetal gene therapy
  vectors used in, 525-526
Fetal long-chain 3-hydroxyacyl-CoA dehydrogenase, *see* Maternal liver disease(s), fetal LCHAD deficiency and
Fetal-maternal interactions, and maternal liver disease, 109-110
Fetal myelomeningocele, *see* Myelomeningocele, fetal surgery for
Fetal-neonatal metabolic transition, FAO and, 100-101
Fetal obstructive uropathy, *see* Obstructive uropathy, fetal surgery for
Fetal risks of fetal HSCTx, 520-521
Fetal surgery
  of cystic hygroma, 351-352
  introduction to, 435-436
  use of embryofetoscopy in, 429-430 *see also* Airway obstruction, fetal surgery for; Anesthesia for fetal surgery; Center for Fetal Diagnosis and Treatment; Fetal gene therapy; Hematopoietic stem cell transplantation, fetal; Life-threatening fetal malformations, open fetal surgery for; Monochorionic twin pregnancy, fetoscopy for complications of; Myelomeningocele, fetal surgery for; Obstructive uropathy, fetal surgery for; Ultrafast magnetic resonance imaging, fetal anomalies diagnosed with
Fetal therapy, *see* Fetal cell therapy; Fetal surgery; Therapy and management of fetal and neonatal cystic hygroma *and specific conditions*
Fetal transplantation, *see* Hematopoietic stem cell transplantation, fetal
Fetal trifunctional protein (TFP) deficiency
  maternal liver disease and, 108
  neonatal FAO disorders and, 103-105
Fetal ultrasound
  of airway obstruction, 499
  of CCAMs, 451-452
  in differential diagnosis of neck masses in cystic hygroma, 348

of neuroblastoma, 265 *see also entries beginning with terms*: Nuchal translucency sonography, first trimester *and specific conditions*
Fetal Wilms' tumor, *see* Wilms' tumor, fetal and neonatal
Fetoscopy, *see* Embryofetoscopy; Monochorionic twin pregnancy, fetoscopy for complications of
Fibrinolytic systems, coagulation and, in preeclampsia, 49-50
Fibrosarcoma, infantile, 300-301
Fibrosis, cystic, lung-directed fetal gene therapy for, 527
First trimester screening and diagnosis
introduction to, 357-358
see also Amniocentesis, first trimester; Chorionic villus sampling, first trimester; Embryofetoscopy; Fetal cell(s) in maternal circulation, first trimester screening for; Serum biochemical markers, first trimester screening with *and entries beginning with terms*: Nuchal translucency sonography, first trimester
Fish oils, prevention of preeclampsia with, 61, 62
Follow-up
by CFDT, 538-539
on electrospray MS/MS, 187-189
on neuroprotective therapy following severe birth asphyxia, 231
Fractures, *see* Temporary brittle bone disease, perinatal
Free β-hCG (β-human chorionic gonadotropin) in first trimester screening, 364-366
measurement of, 365-366
for trisomy 18 and potential obstetrical complications, 364
see also Free β-hCG in first trimester screening for Down's syndrome
Free β-hCG (β-human chorionic gonadotropin) in first trimester screening for Down's syndrome, 359-365
biology and chemistry of, 364-365
hCG compared with, 362-363
PAPP-A combined with, 363
Free radicals
O_2-, in preeclampsia, 29
secondary neuronal injury due to, 227
Frequency
of end-of-life decisions for neonates, 235
of fetal cells in maternal blood at different gestational ages, 394-395
Fumarase deficiency, 117
FWT (familial Wilms' tumor), 314

Gastrointestinal system, maternal, anesthesia for fetal surgery and, 508
GBS, *see* Group B *Streptococcus* meningitis, neonatal
Gene therapy, *see* Fetal gene therapy
General requirements for end-of-life decisions for neonates
of all types, 240
concerning doctor-parent relationship, 240-241
Genetic counseling
for cystic hygroma, 353
nondirective, for HSCTx, 521
Genetic disorders and syndromes
associated with cystic hygroma, 345
first trimester nuchal translucency sonography in detection of, 386; *see also* Nuchal translucency sonography, first trimester, screening for aneuploidy with; Serum biochemical markers, first trimester screening for aneuploidy with
see also specific conditions
Genetics
of congenital leukemia, 276
cytogenetic abnormalities in neonatal neuroblastoma, 264
in fetal cell analysis, 396-397
of fetal and neonatal cystic hygroma, 342-345
of LCH, 322-323
of LCHAD and TFP deficiencies, 103-105
of neonatal leukemia, 276
of neonatal WT, 312-313
see also DNA; Families; Fetal gene therapy; Genetic counseling; Genetic disorders and syndromes; Genetics of preeclampsia; Genotype; Inborn errors of metabolism, neonatal; Inflammatory cascade triggered by neonatal GBS meningitis, deregulation of COX and NOS gene expression in; Inheritance; Karyotypes; Microchimerism; Molecular genetics; Mosaicism; RNA *and specific genes*
Genetics of preeclampsia, 14-23
factor V Leiden mutation in, 20-21, 52
mutation of allele T235 of *AGT* gene in, 18-20, 52
pathophysiology and, *see* Pathophysiology of preeclampsia
Genotype, correlation between phenotype and, in LCHAD deficiency, 107
Gestational age(s)
frequency of fetal cells in maternal blood at different, 394-395
see also First trimester screening and diagnosis; Premature infants; Second trimester screening
Glucose intolerance, and preeclampsia, 53
Glycogenoses, *see* Glycolytic-glycogenolytic metabolic defect(s), neonatal metabolic myopathies and
Glycolytic-glycogenolytic metabolic defect(s), neonatal metabolic myopathies and, 126-133
AMD as, 126-128
branching enzyme deficiency as, 128, 132-133
debrancher deficiency as, 128, 130-131
PBK deficiency as, 128-129
PFK deficiency as, 128, 131-132
PGK deficiency as, 128, 132
phosphorylase deficiency as, 128-130
Gonadotropin, human chorionic, free β-hCG compared with, 362-363; *see also entries beginning with*: Free β-hCG
Granuloma, neonatal pyogenic, 337
Great vessels, defects of, first trimester nuchal translucency sonography in detection of, 384-386

Group B *Streptococcus* (GBS) meningitis, neonatal, 219, 223, 224
see also Inflammatory cascade triggered by neonatal GBS meningitis, deregulation of COX and NOS gene expression in
Growth and development
embryonic, embryofetoscopy in study of, 427-428
neonatal Wilms' tumor and disorders of, 315-316
see also Neurodevelopmental handicaps
Guanosine triphosphate (GTP) cyclohydrolase deficiency, 196-197
autosomal dominantly inherited, 196
compound heterozygotes with, 196-197

Hamartoma, eccrine angiomatous, neonatal, 337
Hashimoto-Pritzker disease in infancy, 327-328
hCG (human chorionic gonadotropin), free β-hCG compared with, 362-363; *see also entries beginning with*: Free β-hCG
HELLP (hemolysis, elevated liver enzymes, and low platelet counts), 105-109
described, 106
and fetal LCHAD deficiency, 107-109
Hemangioma, neonatal, 334-336
Hemangiopericytoma, congenital, 337
Hematophagocytic lymphohistiocytosis (HLH) of infancy, 326-327
Hematopoietic stem cell(s), cultures of, in detection of fetal cells in maternal blood, 396
Hematopoietic stem cell (HSC)-directed fetal gene therapy, 532
Hematopoietic stem cell transplantation (HSCTx), fetal, 515-523
candidate diseases for, *see* Candidate diseases for HSCTx
clinical experience with, 516, 517
diseases unlikely to benefit from, 520
experimental support for, 515-516
maternal and fetal risks of, 520-521
nondirective counseling for, 521
Hemodynamics
in preeclampsia, $MgSO_4$ effects on, 67-68
see also Blood flow; Hypertension in preeclampsia; Uteroplacental circulation
Hemoglobinopathies, as candidates for HSCTx, 519-520
Hemolysis, elevated liver enzymes, and low platelet counts, *see* HELLP
Hemophagocytic lymphohistiocytosis of infancy, 326-327
Hemorrhages
early-onset intraventricular, in preterm infants, incidence of neurodevelopmental handicaps with, 212-217
see also Hemorrhages in severe preeclampsia, management of
Hemorrhages in severe preeclampsia, management of, 86-88
cerebral, 86
hepatic, 87-88
Hepatic failure syndrome, neonatal, neurological distress with, 172
Hepatic rupture in severe preeclampsia, management of, 87-88
Hereditary tyrosinemia type I, neonatal, neurological distress and, 172
Hernia, *see* Diaphragmatic hernia
Heterogeneity, clinical, of neonatal neuroblastoma, biological basis of, 263-264
HHH (hyperornithinemia-hyperammonemia-homocitrullinuria) syndrome, neonatal, neurological distress and, 167
High airway obstruction syndrome, congenital, *see* Airway obstruction, fetal surgery for
High-carbohydrate, low-fat diet, as therapy of FAO disorders, 142
High-risk neuroblastoma
considerations for assessment of, 268, 269
management of, 271
High-risk populations for aneuploidy, first trimester nuchal translucency sonography of, 371-372
Histiocytes, differential characteristics of, 321
Histiocytoid cardiomyopathy, and Complex III deficiency, 118
Histiocytosis(es) of infancy, 319-331
biology of, 319-321
classification of, 321-322
Hashimoto-Pritzker disease as, 327-328
HLH as, 326-327
juvenile xanthogranuloma and benign cephalic histiocytosis as, 328
Langerhans cell, 322-325
Histology
histopathologic classification of neonatal neuroblastoma, 264
of neonatal neuroblastoma, 268
of sacrococcygeal teratoma, 457
HLH (hemophagocytic lymphohistiocytosis) of infancy, 326-327
HMG-CoA (3-hydroxy-3-methylglutaryl-CoA) lyase deficiency, neonatal, neurological distress and, 171
HSC, *see* Hematopoietic stem cell(s); Hematopoietic stem cell-directed fetal gene therapy; Hematopoietic stem cell transplantation, fetal
HSCTx, *see* Hematopoietic stem cell transplantation, fetal
HT1 (hypertyrosinemia type I), liver-directed fetal gene therapy for, 530
Human chorionic gonadotropin (hCG), free β-hCG compared with, 362-363; *see also entries beginning with*: Free β-hCG
Human embryology, embryofetoscopic study of, 427-428
Human milk fat globule (MFG), protective function of, 242-249
characteristic and function of MFG membrane, 242-245
triglycerides as core of, 245-247
3-Hydroxyacyl-CoA dehydrogenase, long-chain, *see* Maternal liver disease(s), fetal LCHAD deficiency and
3-Hydroxy-3-methylglutaryl-CoA (HMG-CoA) lyase deficiency, neonatal, neurological distress and, 171

β-Hydroxy-γ-trimethylammonium butyrate, *see* Carnitine in neonatal metabolic myopathies due to FAO disorders; Primary and secondary neonatal carnitine deficiency
Hygroma, *see* Cystic hygroma, fetal and neonatal
Hyperammonemia, neonatal, neurological distress and, 164-171
  ketosis and, 167-171
Hyperglycinemia, neonatal nonketotic, neurological distress and, 171
Hyperinsulinemia, chronic, hypertension and, in preeclampsia, 7-9
Hyperornithinemia-hyperammonemia-homocitrullinuria (HHH) syndrome, neonatal, neurological distress and, 167
Hyperphenylalaninemia, tetrahydrobiopterin metabolic defects with and without, 196-197
Hypertension in preeclampsia
  and antihypertensive drugs in prevention of preeclampsia, 62
  chronic hyperinsulinemia and, 7-9
  $MgSO_4$ effects on, and eclamptic seizure prevention, 68-69
Hypertyrosinemia type I (HT1), liver-directed fetal gene therapy for, 530
Hypervolemia of pregnancy, *ATG* T235 gene mutation and failed, preeclampsia and, 19-20
Hypoglycemia, hypoketotic, neonatal metabolic myopathies due to FAO disorders and, 134
Hypoketotic hypoglycemia, neonatal metabolic myopathies due to FAO disorders and, 134
Hypothermia, as neuroprotective therapy of severe birth asphyxia, 227-229

IF (infantile fibrosarcoma), 300-301
Immunology
  in normal pregnancy, 25-26
  see also Immunology of preeclampsia
Immunology of preeclampsia, 24-33
  origins of preeclampsia and, *see* Etiology of preeclampsia
  uteroplacental circulation and, 26
  vasoconstriction and, 26
Immunophenotypes of blasts in neonatal acute leukemia, 280
Inborn errors of metabolism, neonatal
  introduction to, 99
  see also Electrospray tandem mass spectrometry, neonatal screening with, for inborn errors of metabolism; Fatty acid β-oxidation; Fatty acid oxidation disorders, neonatal; Fatty acid oxidation disorders, neonatal metabolic myopathies due to; Glycolytic-glycogenolytic metabolic defect(s), neonatal metabolic myopathies and; Maternal liver disease(s), fetal LCHAD deficiency and; Monoamine neurotransmission, metabolic disorders of; Neonatal amino acid and organic acid disorders; Neonatal mitochondrial metabolic disorders; Primary and secondary neonatal carnitine deficiency; Temporary brittle bone disease, perinatal
Incidence, 212-218
  of end-of-life decisions for neonates, 236
  of fetal and neonatal cystic hygroma, 341, 342
  of neonatal bacterial meningitis, 218
  of neonatal leukemia, 274-275
  of neonatal vascular tumors, 332-334
  of neurodevelopmental handicaps with early-onset IVH in preterm infants, 212-217
  see also Incidence of histiocytosis of infancy
Incidence of histiocytosis of infancy
  HLH, 326
  LCH, 322
Indications
  for CVS, 405-406
  for pulmonary artery catheter in severe preeclampsia, 82-84
  see also specific conditions
Individual genetic defects in FAO disorders, specific features of, 135-137
Infantile fibrosarcoma (IF), 300-301
Infantile myofibromatosis/congenital hemangiopericytoma, 337
Inflammatory cascade triggered by neonatal GBS meningitis, deregulation of COX and NOS gene expression in, 250-260
  biochemical characterization of, 255-256
  biochemical mediators of, 251-252
  molecular characterization of, 256
  NO in, 253-256
  pathophysiological consequences of inflammation leading to brain injury, 251
  PGs in, 251, 254-256
  TNF-α in, 251-256
Inheritance
  of AMD, 128
  of branching enzyme deficiency, 133
  of debrancher deficiency, 130
  of PFK deficiency, 131
  of PGK deficiency, 132
  of phosphorylase deficiency, 129
  see also Genetics
Injury
  brain, pathophysiological consequences of inflammation in GBS meningitis leading to, 251
  see also Secondary neuronal injury, severe birth asphyxia due to
Insulin resistance, and preeclampsia, 53
Intergenomic signaling defects, neonatal mitochondrial disorders and, 115, 119
Intermediate-risk neuroblastoma, 268-271
  considerations for assessment of, 268, 269
  management of, 270-271
Interviews of pediatricians involved in end-of-life decisions, 236-239
Intrauterine mortality rates of aneuploid fetuses, first trimester nuchal translucency sonography and, 375-376
Intraventricular hemorrhage (IVH), early-onset, in preterm infants, incidence of neurodevelopmental handicaps with, 212-217

Intrinsic airway defects, fetal airway obstruction due to, 495-496
In utero origin of neonatal leukemia, 275-276
Ischemia, uteroplacental, in preeclampsia, 2-5, 15, 27
Isolated omental artery, reactivity of, in preeclampsia, 38-39
Isovaleric acidemia, neonatal, neurological distress and, 170
IVH (intraventricular hemorrhage), early-onset, in preterm infants, incidence of neurodevelopmental handicaps with, 212-217

Juvenile xanthogranuloma of infancy, 328

Kaposiform hemangioendothelioma (KHE), neonatal, 336
Karyotypes
  of blasts in neonatal acute leukemia, 280
  of cystic hygroma fetuses, chromosomal constitution of, 345
α (alpha)-Ketoglutarate dehydrogenase deficiency, 115, 117
Ketosis, and neonatal hyperammonemia, neurological distress and, 167-171
KHE (Kaposiform hemangioendothelioma), neonatal, 336
Krebs cycle disorders, neonatal mitochondrial disorders and, 115-117

Labor, preterm, during anesthesia for fetal surgery, prevention of, 508-510
Laboratory data, 126-133
  on AMD, 126-127
  on branching enzyme deficiency, 132-133
  on debrancher deficiency, 130
  on neonatal leukemia, 279-280
  on neonatal metabolic myopathies, 135, 137-139
  on PBK deficiency, 128
  on PFK deficiency, 131
  on PGK deficiency, 132
  on phosphorylase deficiency, 129
  see also Serum biochemical markers, first trimester screening with *and specific conditions*
Langerhans cell histiocytosis (LCH) of infancy, 322-325
Large-scale rearrangements of mitochondrial DNA, respiratory chain disorders and, 115, 120
Laser ablation, fetoscopic, for TTTS, 479-481
LCH (Langerhans cell histiocytosis) of infancy, 322-325
LCHAD (long-chain 3-hydroxyacyl-CoA dehydrogenase), *see* Maternal liver disease(s), fetal LCHAD deficiency and
Leakage of amniotic fluid, as early amniocentesis complication, 419
Leukemia, neonatal, 274-285
  acute lymphocytic, 278-279
  acute myelogenous, 277, 278
  clinical presentation of, 276-277
  differential diagnosis of, 280-282
  etiology of, 275
  genetics of, 276
  incidence of, 274-275
  laboratory findings on, 279-280
  supportive care and therapy of, 282
  twin studies and in utero origin of, 275-276
Life-sustaining treatment for neonates, decision to forgo, 240
Life-threatening fetal malformations, open fetal surgery for, 448-461
  for CDH, *see* Congenital diaphragmatic hernia, open fetal surgery for
  complications of, 449-450
  for lung lesions, *see* Congenital cystic adenomatoid malformations, open fetal surgery for
  postoperative care in, 449
  preoperative evaluation and care for, 448-449
  for sacrococcygeal teratoma, 457-459
Lipoblastoma of infancy, 306
Liposarcoma of infancy, 306
Liver, *see* Liver-directed fetal gene therapy; Maternal liver disease(s), fetal LCHAD deficiency and *and entries beginning with term*: Hepatic
Liver-directed fetal gene therapy, 529-532
  for HT1, 530
  for OTC deficiency, 529-530
  results of, 530-532
Long-chain 3-hydroxyacyl-CoA dehydrogenase, *see* Maternal liver disease(s), fetal LCHAD deficiency and
Low-dose aspirin, preeclampsia prevention with, 59-60
Low-risk neuroblastoma, 268-270
  considerations for assessment of, 268, 269
  management of, 270
Low-salt diet, prevention of preeclampsia with, 62
Lower urinary tract obstructions, *see* Obstructive uropathy, fetal surgery for
Lung-directed fetal gene therapy, 526-529
  for CF, 527
  results of, 527-529
  for SPB deficiency, 526-527
LUTOs (lower urinary tract obstructions), *see* Obstructive uropathy, fetal surgery for
Lymphangioma
  fetal cervical, airway obstruction due to, 497-498
  see also Cystic hygroma, fetal and neonatal
Lymphoblastic leukemia, neonatal acute, 278-279
Lymphohistiocytosis, hematophagocytic, of infancy, 326-327

Magnesium sulfate ($MgSO_4$)
  prevention of preeclampsia with, 61
  see also Magnesium sulfate in prevention of eclamptic seizures
Magnesium sulfate ($MgSO_4$) in prevention of eclamptic seizures
  CPP before and after, 74-75
  effects of antihypertensive properties of, 68-69
  efficacy of, 66
  hemodynamic effects of, 67-68

mechanisms of action of, 67-69
seizure rate in patients on, 72-73
Magnetic resonance imaging, *see* Ultrafast magnetic resonance imaging, fetal anomalies diagnosed with
Malformations and anomalies
associated with cystic hygroma, 345
fetal, *see* Fetal anomalies
see also entries beginning with term: Congenital *and specific malformations*
Malignancies, *see* Neonatal tumors *and specific malignancies*
Mammalian fatty acid oxidation (FAO), 100-101
Maple syrup urine disease (MSUD), neonatal, neurological distress and, 167-169
Mass(es)
neonatal soft tissue, 300
see also Abdominal mass; Mass(es) in neonatal neuroblastoma; Neck masses, fetal, diagnosis of *and specific conditions*
Mass(es) in neonatal neuroblastoma, 265-267
abdominal, 265
cervical and mediastinal, 266
unexplained, 266-267
Mass spectrometry, *see* Electrospray tandem mass spectrometry, neonatal screening with, for inborn errors of metabolism
Maternal circulation, *see* Fetal cell(s) in maternal circulation, first trimester screening for
Maternal considerations in anesthesia for fetal surgery, 507-510
cardiovascular system considerations, 507-508
gastrointestinal and nervous system considerations, 508
and prevention of preterm labor, 508-510
respiratory system considerations, 507
Maternal-fetal unit of CFDT, 538
Maternal liver disease(s), fetal LCHAD deficiency and, 100-112
AFLP and HELLP as, *see* Acute fatty liver of pregnancy; HELLP
FAO and, *see* Fatty acid oxidation disorders, neonatal
implications of, and recommendations for evaluation of families with, 110-111
mechanisms of fetal-maternal interactions and, 109-110
Maternal risks of fetal HSCTx, 520-521
Maternally transmitted point mutations, respiratory chain disorders and, 115, 120-121
MCT (medium-chain triglyceride) oil in therapy of FAO disorders, 142
Mechanical changes in vessels of preeclamptic patients, 41
Mediastinal mass in neonatal neuroblastoma, 266
Medium-chain triglyceride (MCT) oil in therapy of FAO disorders, 142
Meningitis, *see* Neonatal bacterial meningitis
Mesoblastic nephroma (MN), neonatal Wilms' tumor and, 311-312
Metabolic decompensation
associated with fasting adaptation in FAO disorders, 134
neonatal neurological distress without, 171-172
Metabolic myopathies, neonatal, *see* Fatty acid oxidation disorders, neonatal metabolic myopathies due to; Glycolytic-glycogenolytic metabolic defect(s), neonatal metabolic myopathies and
Metabolic profiling, neonatal, with electrospray MS/MS, 184-185
Metabolic transition, fetal-neonatal, FAO and, 100-101
Metabolism, *see* Inborn errors of metabolism, neonatal *and entries beginning with term*: Metabolic
Methylmalonic acidemia (MMA), neonatal, neurological distress and, 169, 170
Mevalonic aciduria, neonatal, neurological distress and, 171
MFG (milk fat globule), *see* Human milk fat globule, protective function of
$MgSO_4$, *see* Magnesium sulfate
Microchimerism of fetal cells in maternal circulation, 398-399
Microvessels, cerebral, *see* Neonatal bacterial meningitis
Mild tetrahydrobiopterin metabolic defects, hyperphenylalaninemia with, 196
Milk fat, *see* Human milk fat globule, protective function of
Minimal engraftment requirement for amelioration, diseases with, as candidates for HSCTx, 520
Miscellaneous sarcomas of infancy, 306-307
Mitochondrial DNA (deoxyribonucleic acid) defects of respiratory chain, 115, 119-121
Mitochondrial metabolic disorders, *see* Neonatal mitochondrial metabolic disorders
Mitochondrial protein importation defects, neonatal mitochondrial disorders and, 115, 119
MMA (methylmalonic acidemia), neonatal, neurological distress and, 169, 170
MMC, *see* Myelomeningocele, fetal surgery for
MN (mesoblastic nephroma), neonatal WT and, 311-312
Models of preeclampsia, *see* Preeclampsia, models of
Molecular genetics, 128-132
of AMD, 128
of debrancher deficiency, 131
of inflammation triggered by neonatal GBS meningitis, 256
of neonatal metabolic myopathies due to FAO disorders, 141
of PBK deficiency, 128-129
of PFK and PGK deficiencies, 132
of phosphorylase deficiency, 130
Molybdenum cofactor deficiency, neonatal, neurological distress and, 172
Monoamine neurotransmission, metabolic disorders of, 194-203
defects affecting monoamine neurotransmission mechanisms, 198, 200-201

diagnosis and therapy of, 198-201
presentation and clinical features of, 195-197
and primary defects affecting monoamine biosynthesis, 197-198
synthesis and catabolism of serotonin and catecholamines and, 194-195
Monoamine oxidase A deficiency, diagnosis and therapy of, 200
Monoamniotic presentation of monochorionic twins, fetoscopy for, 474-475
Monochorionic twin pregnancy, fetoscopy for complications of, 474-483
for monoamniotic twin pregnancy, 474-475
for monochorionic twins discordant for anomalies, 475-476
for TRAP sequence, 476-478
for TTTS, 478-481
Morbidity
with neonatal bacterial meningitis, 220
see also specific conditions
Mortality
due to neonatal bacterial meningitis, 220, 222-223
intrauterine, of aneuploid fetuses, first trimester nuchal translucency sonography and, 375-376
see also Death *and specific conditions*
Mosaicism, confined placental, detected with first trimester CVS, 407-408
MRI (magnetic resonance imaging), *see* Ultrafast magnetic resonance imaging, fetal anomalies diagnosed with
MS/MS (tandem mass spectrometry), *see* Electrospray tandem mass spectrometry, neonatal screening with, for inborn errors of metabolism
MSUD (maple syrup urine disease), neonatal, neurological distress and, 167-169
Multidisciplinary team of specialists in CFDT, 536
Multiple carboxylase deficiency, neonatal, neurological distress and, 170-171
Multiple gestations
first trimester CVS in detection of, 410-411
see also Twin(s)
Muscle, *see* Muscle biopsy; Musculoskeletal complications *and entries beginning with element*: Myo-
Muscle biopsy
in branching-enzyme deficient patients, 133
in PFK-deficient patients, 131
in PGK-deficient patients, 132
in phosphorylase-deficient patients, 129
Musculoskeletal complications of early amniocentesis, 420-421
Mutation(s)
maternally transmitted point, respiratory chain disorders and, 115, 120-121
see also Mutation(s) in LCHAD and TFP deficiencies; Mutation(s) in preeclampsia
Mutation(s) in LCHAD and TFP deficiencies
E474Q, 103-105
R255*ter* and R524*ter*, 105
Mutation(s) in preeclampsia
of allele T235 of *AGT* gene, 18-20, 52
of factor V Leiden, 20-21, 52
MVs (microvessels), cerebral, *see* Neonatal bacterial meningitis
Myelogenous leukemia, neonatal acute, 277, 278
Myelomeningocele (MMC), fetal surgery for, 462-473
early experience with, 469-471
embryology of MMC, 462-463
preoperative assessment and patient selection for, 465-466
the procedure, 466-469
rationale for surgery, 463-464
timing of, 464-465
Myeloproliferative disorder, transient, differential diagnosis between neonatal acute leukemia and, 281-282
Myofibromatosis, infantile, 337
Myopathies, neonatal
histocytoid cardiomyopathy, Complex III deficiency and, 118
metabolic, *see* Glycolytic-glycogenolytic metabolic defect(s), neonatal metabolic myopathies and; Fatty acid oxidation disorders, neonatal metabolic myopathies due to

NaCl (sodium chloride; table salt), preeclampsia prevention with diet low in, 62
NADH (nicotine adenine dinucleotide, oxidized)-ubiquinone reductase (complex I) deficiency, and mitochondrial disorders of respiratory chain, 115, 118
NAGS (*N*-acetylglutamic acid synthetase) deficiency, neonatal, neurological distress and, 164-165
National Institutes of Health (NIH) Fetal Cell Study, 397
Natural history
of CCAMs, 450-451
of CDH, 454
of increased nuchal translucency, 376
of sacrococcygeal teratoma, 457
Neck masses, fetal, diagnosis of
in neuroblastoma, ultrasound in differential diagnosis, 347, 348
with ultrafast MRI, 441-442
see also specific neck masses
Negative results, false-, with electrospray MS/MS, 190-191
Neonatal amino acid and organic acid disorders, 162-173
diagnosis of, 162-164, 170
neurologic distress and, *see* Neurological distress, neonatal, amino and organic acidopathies and
Neonatal bacterial meningitis, 218-225
diagnosis of, 219
incidence of, 218
morbidity with, 220
mortality due to, 220, 222-223
organisms responsible for, 218-219, 221-222, 224;

see also Group B *Streptococcus* meningitis, neonatal
prospective study of, 220-224
treatment of, 219-220, 223-225
see also Inflammatory cascade triggered by neonatal GBS meningitis, deregulation of COX and NOS gene expression in
Neonatal considerations in management of cystic hygroma, 351
Neonatal fatty acid oxidation disorders, *see* Fatty acid oxidation disorders, neonatal
Neonatal inborn errors of metabolism, *see* Inborn errors of metabolism, neonatal
Neonatal mitochondrial metabolic disorders, 113-124
due to Krebs cycle disorders, 115-117
due to pyruvate metabolism disorders, 114-116
due to translocase defects, mitochondrial protein importation defects, and intergenomic signaling defects, 115, 119
of respiratory chain, *see* Respiratory chain, neonatal mitochondrial disorders of
Neonatal myopathies, *see* Myopathies, neonatal
Neonatal tumors
introduction to, 261-262
see also Brain tumors, neonatal; Cystic hygroma, fetal and neonatal; Histiocytosis(es) of infancy; Leukemia, neonatal; Neuroblastoma, neonatal; Soft tissue sarcoma(s) of infancy; Vascular tumors in infancy; Wilms' tumor, fetal and neonatal
Nephroblastoma, *see* Wilms' tumor, fetal and neonatal
Nephrogenic rests (NR), neonatal WT and, 312
Nephroma, mesoblastic, neonatal WT and, 311-312
Nervous system
central, *see* Central nervous system
maternal, anesthesia for fetal surgery and, 508
sympathetic nervous system model of preeclampsia, 9
see also Monoamine neurotransmission, metabolic disorders of *and entries beginning with element*: Neuro-
Neuroblastoma, neonatal, 263-273
biologic basis of clinical heterogeneity of, 263-264
clinical features of, 265-267
diagnosis of, 268-270
management of, 270-271
staging of, 267-268
Neurodevelopmental handicaps
incidence of, with early-onset IVH in preterm infants, 212-217
introduction to, 211
see also End-of-life decisions for neonates, study on; Human milk fat globule, protective function of; Neonatal bacterial meningitis; Secondary neuronal injury, severe birth asphyxia due to
Neurological distress, neonatal, amino and organic acidopathies and
with hepatic failure syndrome and hereditary type I tyrosinemia, 172
with hyperammonemia, *see* Hyperammonemia, neonatal, neurological distress and
without metabolic decompensation, 171-172
Neurological system, *see* Nervous system
Neuromuscular disease, neonatal, *see* Fatty acid oxidation disorders, neonatal metabolic myopathies due to; Glycolytic-glycogenolytic metabolic defect(s), neonatal metabolic myopathies and
Neuronal differentiation markers in neonatal neuroblastoma, 264
Neuronal injury, *see* Secondary neuronal injury, severe birth asphyxia due to
Neuroprotective therapy after severe birth asphyxia, 227-231
biological plausibility of, 228
clinical trial of, 230-231
conclusion on, 232
earliest entry point for, 229-230
hypothermia as, 227-229
need for appropriate follow-up instruments and collaborative network in, 231
pharmacokinetics and safety of, 228-229
Neurotransmitters, *see* Monoamine neurotransmission, metabolic disorders of
Neutrophils, markers of activation of, in preeclampsia, 28-29
Nevus, neonatal eccrine, 337
NIH (National Institutes of Health) Fetal Cell Study, 397
Nimodipine, *see* Eclamptic seizures, prevention of
Nimodipine Study Group, members of, 75-76
Nitric oxide (NO)
in inflammation triggered by neonatal GBS meningitis, 253-256
see also Nitric oxide in preeclampsia
Nitric oxide (NO) in preeclampsia, 34-38
Adriamycin effects on, 6-7
effects of plasma from preeclamptic patients on, 40-41
endothelial dysfunction and measurement of, 51
and endothelium relaxation, 36-38
in management of severe preeclampsia, 85-86
NOS inhibition effects on, 5-6, 37-38
vascular reactivity and, 34-36
Nitric oxide synthase, *see* Inflammatory cascade triggered by neonatal GBS meningitis, deregulation of COX and NOS gene expression in; Nitric oxide synthase, preeclampsia and
Nitric oxide synthase (NOS), preeclampsia and
Adriamycin effects on, 6
effects of plasma from preeclamptic patients on, 40-41
inhibition of, 5-6, 37-38
NKH (nonketotic hyperglycinemia), neonatal, neurological distress and, 171
NO, *see* Nitric oxide
Nodules, unexplained masses and, in neonatal neuroblastoma, 266-267
Nondirective counseling for fetal HSCTx, 521

Noninvasive monitoring, *see* Doppler ultrasound of preeclampsia; Fetal ultrasound *and entries beginning with terms*: Nuchal translucency sonography
Nonketotic hyperglycinemia (NKH), neonatal, neurological distress and, 171
Nonsurgical management *see* Dietary therapy; Pharmacotherapies
Nonviral vectors in fetal gene therapy, 526
Normal cells, diseases with selective advantage for, as candidates for HSCTx, 518-519
Normal pregnancy, 24-26
  immunology of, 25-26
  uteroplacental circulation in, 24-25
  as vasodilatory state, 24
NOS (nitric oxide synthase), *see* Inflammatory cascade triggered by neonatal GBS meningitis, deregulation of COX and NOS gene expression in; Nitric oxide synthase, preeclampsia and
NR (nephrogenic rests), neonatal WT and, 312
Nuchal cystic hygroma, fetal posterior, incidence of, 342
Nuchal translucency, fetal structural anomalies and, 386-388
  and increase in nuchal translucency, 382-384
  limitations of studies linking, 387-388
  and prevalence of anomalies, 386-387
  see also Nuchal translucency sonography, first trimester, in detection of fetal structural abnormalities
Nuchal translucency sonography, first trimester, in detection of fetal structural abnormalities, 382-392
  cardiac defects, 384-386
  clinical applications of, 389-390
  diaphragmatic hernia, 385-386
  and embryofetoscopic confirmation of diagnosed structural anomalies, 428
  genetic syndromes, 386
  pathophysiology of nuchal translucency and, 389
  perinatal outcome and increase in nuchal translucency, 388-389
Nuchal translucency sonography, first trimester, screening for aneuploidy with, 369-381
  abnormal nuchal translucency defined, 374-375
  future of, 378-379
  intrauterine mortality rates of aneuploid fetuses and, 375-376
  natural history of increase in nuchal translucency, 376
  in populations at high risk for aneuploidy, 371-372
  quality control in, 375
  technique of, 376-378
  in unselected populations, 372-374
Nuclear DNA (deoxyribonucleic acid) defects of respiratory chain, 117-118

O_2 (oxygen)-free radicals in preeclampsia, 29
Obstetric unit of CFDT, 537-538
Obstetrical complications, *see* Complication(s), obstetrical
Obstruction, *see* Airway obstruction, fetal surgery for; Obstructive uropathy, fetal surgery for
Obstructive uropathy, fetal surgery for, 484-495
  with cystoscopic ablation of posterior urethral valves, 491
  experimental work supporting, 486
  outcome of, 491-493
  preoperative evaluation and patient selection for, 486-490
  with vesicoamniotic shunting, 490-491
Oil
  fish, in prevention of preeclampsia, 61, 62
  MCT, in therapy of FAO disorders, 142
Omental artery, reactivity of isolated, in preeclampsia, 38-39
Oncogene, *c-myc*-related, amplification of, in neonatal neuroblastoma, 264
Open fetal surgery, *see* Life-threatening fetal malformations, open fetal surgery for
Operating room of CFDT, 538
Organic acid metabolic disorders, *see* Neonatal amino acid and organic acid disorders
Organisms responsible for neonatal bacterial meningitis, 218-219, 221-222, 224; *see also* Group B *Streptococcus* meningitis, neonatal
Ornithine-transcarbamylase (OTC) deficiency
  liver-directed fetal gene therapy for, 529-530
  neonatal, neurological distress and, 165-166
OTC deficiency, *see* Ornithine-transcarbamylase deficiency
Outcome, 527-532
  of fetal surgery for obstructive uropathy, 491-493
  of liver-directed fetal gene therapy, 530-532
  of lung-directed fetal gene therapy, 527-529
  perinatal, and increased nuchal translucency, 388-389
  see also Complication(s); Mortality; Prognosis *specific conditions and therapeutic modalities*
Oxidation, *see* Fatty acid oxidation
Oxygen (O_2)-free radicals in preeclampsia, 29

Palliative care of neonates, decision to provide, 240
PAPP-A (pregnancy-associated plasma protein-A) in first trimester screening, 364-366
  measurement of, 365-366
  for potential obstetrical complications and trisomy 18, 364
PAPP-A (pregnancy-associated plasma protein-A) in first trimester screening for Down's syndrome, 359-363
  biology and chemistry of, 364-365
  free β-hCG combined with, 363
Paraplegia, and neonatal neuroblastoma, 265-266
Parents, end-of-life decisions for neonates and
  and doctor-parent relationship, 240-241
  role of, 238
Paresis, upper extremity, and neonatal neuroblastoma 265-266
Pathology and pathophysiology, 130-133
  of AMD, 127-128

of branching enzyme deficiency, 132-133
of CCAMs, 451
of CDH, 454-455
of debrancher deficiency, 130-131
of fetal and neonatal cystic hygroma, 345-346
of nuchal translucency in fetal structural abnormalities, 389
pathophysiological consequences of inflammation triggered by neonatal GBS meningitis leading to brain injury, 251
of PFK deficiency, 131-132
of PGK deficiency, 132
of phosphorylase deficiency, 130
of sacrococcygeal teratoma, 457-458
of vascular tumors in infancy, 332, 334
see also Pathophysiology of preeclampsia *and specific conditions*
Pathophysiology of preeclampsia, 15-18
failure of spiral artery remodeling in, 3, 15-17, 19, 26, 53
placental ischemia hypothesis of, 2-5, 15, 27
primiparous preponderance in, 17-18
renal, 17, 54
Patient-doctor relationship, end-of-life decisions for neonates and, 240-241
Patient evaluation
by CFDT, 537
see also Preoperative patient evaluation for fetal surgery
Patient history, metabolic myopathy patients, 139
Patient referral program of CFDT, 536-537
Patient selection for fetal surgery
of MMC, 465-466
of obstructive uropathy, 486-490
PBK (phosphorylase b kinase) deficiency, neonatal metabolic myopathies and, 128-129
PDHC (pyruvate dehydrogenase complex) deficiency, 114-116
Peptide hormones, placental, in preeclampsia, 53
Perfusion
fetoscopy for twin reversed arterial perfusion sequence, 476-478
see also Cerebral perfusion pressure, prevention of eclamptic seizures and
Perinatal outcome, and increase in nuchal translucency, 388-389
Perinatal temporary brittle bone disease, *see* Temporary brittle bone disease, perinatal
Perioperative management of fetus as surgical patient, 512-513
Perlman syndrome (PS) with WT, 315
PFK (phosphofructokinase) deficiency, neonatal metabolic myopathies and, 128, 131-132
PGK (phosphoglycerate kinase) deficiency, neonatal metabolic myopathies and, 128, 132
PGs, *see* Prostaglandins
Pharmacokinetics of neuroprotective therapy, 228-229
Pharmacotherapies
of fetal and neonatal cystic hygroma, 352-353
investigational, for severe preeclampsia, 84-86
see also specific pharmacologic agents; for example, Magnesium sulfate in prevention of eclamptic seizures *and specific conditions*
Phenotype-genotype correlation in LCHAD deficiency, 107
Phosphofructokinase (PFK) deficiency, neonatal metabolic myopathies and, 128, 131-132
Phosphoglycerate kinase (PGK) deficiency, neonatal metabolic myopathies and, 128, 132
Phosphorylase b kinase (PBK) deficiency, neonatal metabolic myopathies and, 128-129
Phosphorylase deficiency, neonatal metabolic myopathies and, 128-130
Physical examination for neonatal metabolic myopathies due to FAO disorders, 139
Physiologic changes in pregnancy, preeclampsia and failure of, 15-17, 19
Placenta, *see* Placental mosaicism; Placental peptide hormones *and entries beginning with term:* Uteroplacental
Placental mosaicism, confined, detected with first trimester CVS, 407-408
Placental peptide hormones in preeclampsia, 53
Planning of discharge by CFDT, 538
Plasma, preeclamptic patient, effects of, 39-41
Plasma carnitine in neonatal metabolic myopathies due to FAO disorders, 134-135
Plasma protein-A, pregnancy-associated, *see entries beginning with acronym:* PAPP-A
Plasmapheresis for severe preeclampsia, 84-85
Platelet count, low, *see* HELLP
Ploidy
in neonatal neuroblastoma, 264
see also Nuchal translucency sonography, first trimester, screening for aneuploidy with; Serum biochemical markers, first trimester screening for aneuploidy with *and specific conditions*
Point mutations, maternally transmitted, respiratory chain disorders and, 115, 120-121
Positive results, false-, with electrospray MS/MS, 190-191
Posterior nuchal cystic hygroma, fetal, incidence of, 342
Posterior urethral valves, fetoscopic cystoscopic ablation of, in obstructive uropathy, 491
Postmortem diagnosis of FAO disorders in sudden and unexpected death, 204-210
Postoperative care of open fetal surgery patients, 449
Precipitating factors in FAO disorders, 141-142
Predictor(s) of preeclampsia, 45-57
clinical risk factors as, 48-49
coagulation and fibrinolytic systems as, 49-50
endothelial dysfunction as, 50-51
etiology and, 47-48; *see also* Etiology of preeclampsia
genetic factors as, *see* Genetics of preeclampsia
insulin resistance and glucose intolerance as, 53
placental peptide hormones as, 53
prostaglandins as, 51-52
renal, 17, 54
uteroplacental blood flow velocity as, 53-54

Preeclampsia
associated with fetal LCHAD, 107-109
described, 106
introduction to, 1
see also Eclamptic seizures, prevention of; Genetics of preeclampsia; Immunology of preeclampsia; Predictor(s) of preeclampsia; Preeclampsia, models of; Prevention of preeclampsia; Severe preeclampsia, management of; Vascular reactivity in preeclampsia
Preeclampsia, models of, 2-13
Adriamycin nephropathy model, 6-7
chronic hyperinsulinemia and hypertension model, 7-9; *see also* Hypertension in preeclampsia
chronic NOS inhibition model, 5-6
starvation, calcium deficiency, endotoxin, and sympathetic nervous system models, 9
uteroplacental ischemia model, 2-5
Pregnancy-associated plasma protein-A, *see entries beginning with acronym*: PAPP-A
Premature (preterm) infants, early-onset IVH in, incidence of neurodevelopmental handicaps with, 212-217
Premature (preterm) labor during anesthesia for fetal surgery, prevention of, 508-510
Prenatal conditions and interventions, *see entries beginning with terms*: Fetal, Intrauterine, In utero
Preoperative patient evaluation for fetal surgery
of MMC, 465-466
of obstructive uropathy, 486-490
of open fetal surgery patients, 448-449
Presymptomatic screening of siblings for FAO disorders, 143
Preterm (premature) infants, early-onset IVH in, incidence of neurodevelopmental handicaps with, 212-217
Preterm (premature) labor during anesthesia for fetal surgery, prevention of, 508-510
Prevalence of fetal structural abnormalities, 384-387
of cardiac defects, 384-385
nuchal translucency and, 386-387
Prevention
of preterm labor during anesthesia for fetal surgery, 508-510
see also Eclamptic seizures, prevention of; Prevention of preeclampsia
Prevention of preeclampsia, 58-64
with antihypertensive drugs, diuretics, and low-salt diet, 62
with antithrombotic agents, 58-60
with calcium supplementation, 60, 61
with fish oils, 61, 62
with $MgSO_4$ and zinc supplementation, 61
Primary disorders affecting monoamine biosynthesis, 197-198
Primary and secondary neonatal carnitine (β-hydroxy-γ-trimethylammonium butyrate) deficiency, 152-161
biosynthesis and dietary sources of carnitine, 152-155
diagnosis of, 157-159
FAO and, 155-157
therapy of, 159-160
Primary sites of neonatal neuroblastoma, 265
Primiparous preponderance in pathophysiology of preeclampsia, 17-18
Prognosis
of neonatal brain tumors, 295
see also Outcome
Prophylaxis, *see* Prevention
Propionic acidemia, neonatal, neurological distress and, 169
Prostaglandins (PGs)
in inflammation triggered by neonatal GBS meningitis, 251, 254-256
in preeclampsia, 51-52
Protein
defective mitochondrial importation of, neonatal mitochondrial disorders and, 119
deficient fetal trifunctional, pediatric FAO disorders and, 103-105
lung-directed fetal gene therapy for surfactant protein B deficiency, 526-527
Protein-A, pregnancy-associated plasma, *see entries beginning with acronym*: PAPP-A
PS (Perlman syndrome) with WT, 315
Pulmonary artery catheter, indications for, in severe preeclampsia, 82-84
Pyogenic granuloma of infancy, 337
Pyruvate, metabolic disorders of, and neonatal mitochondrial disorders, 114-116
Pyruvate carboxylase deficiency, 115, 116
Pyruvate dehydrogenase complex (PDHC) deficiency, 114-116

Quality control in nuchal translucency sonography, 375

R255*ter* mutation in LCHAD and TFP deficiencies, FAO and, 105
R524*ter* mutation in LCHAD and TFP deficiencies, FAO and, 105
Radicals, *see* Free radicals
Radiological dogma of fractures in child abuse, 178-181
Reactivity, vascular, *see* Vascular reactivity in preeclampsia
Recognition of fetal cells in maternal blood, 396-397
Referral program of CFDT, 536-537
Renal etiology of preeclampsia, 17, 54
Renal tumors, *see* Wilms' tumor, fetal and neonatal
Respiratory chain, neonatal mitochondrial disorders of, 117-121
and Complex I and Complex III deficiencies, 115, 118
and Complex IV deficiency, 115, 118-119
DNA defects, *see* DNA defects of respiratory chain
Respiratory complications of early amniocentesis, 420-421

Respiratory system, maternal, anesthesia for fetal surgery and, 507
Retroviral vectors in fetal gene therapy, 525
Reversed arterial perfusion sequence, twin, fetoscopy for, 476-478
Rhabdomyosarcoma of infancy, 302-304
Riboflavin (vitamin B_2) in therapy of FAO disorders, 142
Ribonucleic acid (RNA), ribosomal and transfer, maternally transmitted point mutations in, respiratory chain disorders and, 115, 121
Ribosomal RNA (ribonucleic acid), maternally transmitted point mutations in, respiratory chain disorders and, 115, 121
Risk and risk factors
  assessment of neuroblastoma, *see* High-risk neuroblastoma; Intermediate-risk neuroblastoma; Low-risk neuroblastoma
  maternal and fetal, of fetal HSCTx, 520-521
  populations at high-risk for aneuploidy, first trimester nuchal translucency sonography of, 371-372
  for preeclampsia, 48-49
RNA (ribonucleic acid), ribosomal and transfer, maternally transmitted point mutations in, respiratory chain disorders and, 115, 121
Rupture, hepatic, in severe preeclampsia, management of, 87-88

Sacrococcygeal teratoma, open fetal surgery for, 457-459
Safety of neuroprotective therapy, 228-229
Salt (sodium chloride; table salt), preeclampsia prevention with diet low in, 62
Sample(s), *see* Sampling
Sample throughput, automated electrospray MS/MS of inborn errors of metabolism and, 185-186
Sampling
  of fetal blood and tissue with embryofetoscopy, 428-429
  see also Chorionic villus sampling, first trimester; Sample throughput; Second samples for neonatal electrospray MS/MS of inborn errors of metabolism
Sarcomas, *see* Soft tissue sarcoma(s) of infancy
Screening
  for neonatal neuroblastoma, 269-270
  for neonatal WT, 316
  presymptomatic sibling, for metabolic myopathies due to FAO disorders, 143
  see also Diagnosis; Electrospray tandem mass spectrometry, neonatal screening with, for inborn errors of metabolism; First trimester screening and diagnosis
Second samples for neonatal electrospray MS/MS of inborn errors of metabolism, 189-191
  collection of, prior to discharge, 189-190
  false-negative and false-positive results and, 190-191
Second trimester screening
  effectiveness of biochemical markers used in, in first trimester, 360
  of nuchal translucency, 376
Secondary carnitine deficiency, *see* Primary and secondary neonatal carnitine deficiency
Secondary neuronal injury, severe birth asphyxia due to, 226-233
  calcium injury, 226-227
  free radical injury, 227
  neuroprotective therapy after, *see* Neuroprotective therapy after severe birth asphyxia
Seizures, *see* Eclamptic seizures, prevention of
Selection
  of fetal target cells in maternal circulation, 393-395
  patient, *see* Patient selection for fetal surgery
Selective advantage for normal cells, diseases with, as candidates for HSCTx, 518-519
Separation of fetal cells from maternal blood, 393-395
Serotonin, synthesis and catabolism of, 194-195
Serum biochemical markers, first trimester screening with
  nuchal translucency screening combined with, 378
  see also Serum biochemical markers, first trimester screening for aneuploidy with
Serum biochemical markers, first trimester screening for aneuploidy with, 359-368
  for Down's syndrome, *see* Down's syndrome, first trimester screening for, with serum biochemical markers
  with free β-hCG, *see* Free β-hCG in first trimester screening
  and obstetrical complications, 364
  with PAPP-A, *see* PAPP-A in first trimester screening
  for trisomy 18, 364
Severe preeclampsia, management of, 79-90
  of complications of, 86-88
  delivery of patients with, 81-82
  expectant management of, 79-81
  and indications for pulmonary artery catheter, 82-84
  investigational pharmacotherapies for, 84-86
Severe tetrahydrobiopterin metabolic defects, hyperphenylalaninemia with, 196
Shunting, vesicoamniotic, for fetal obstructive uropathy, 490-491
Siblings
  presymptomatic screening of, for metabolic myopathies due to FAO disorders, 143
  see also Twin(s)
Signaling defects, intergenomic, neonatal mitochondrial disorders and, 115, 119
Simpson-Golabi-Behmel syndrome with WT, 315-315
Sodium chloride (NaCl; table salt), preeclampsia prevention with diet low in, 62
Soft tissue sarcoma(s) of infancy, 299-309
  characteristics and differential diagnosis of, 300
  common, 300-302

rhabdomyosarcoma as, 302-304
therapy and management of, 307
uncommon, 304-307
Sonography, *see* Doppler ultrasound of preeclampsia; Fetal ultrasound *entries beginning with terms*: Nuchal translucency sonography *and specific conditions*
Sotos syndrome associated with neonatal WT, 316
SPB (surfactant protein B) deficiency, lung-directed fetal gene therapy for, 526-527
Specialists, CFDT multidisciplinary team of, 536
Specific features of individual genetic defects in FAO disorders, 135-137
Specific requirements of end-of-life decisions for neonates, 240
Spectrometry, *see* Electrospray tandem mass spectrometry, neonatal screening with, for inborn errors of metabolism
Spiral artery remodeling, failure of, in preeclampsia, 3, 15-17, 19, 26, 53
Spread patterns of neonatal neuroblastoma, 265
Staging of neonatal neuroblastoma, 267-268
Starch, uncooked corn, as therapy of FAO disorders, 142
Starvation model of preeclampsia, 9
Stem cell(s), *see* Hematopoietic stem cell(s); Hematopoietic stem cell-directed fetal gene therapy; Hematopoietic stem cell transplantation, fetal
Structural abnormalities, *see* Nuchal translucency, fetal structural anomalies and; Nuchal translucency sonography, first trimester, in detection of fetal structural abnormalities *and specific conditions*
Structural changes, vascular, in preeclampsia, 41
Structural genes, maternally transmitted point mutations in, respiratory chain disorders and, 115, 120-121
Sudden and unexpected death, postmortem diagnosis of FAO disorders in, 204-210
Sulfate oxidase deficiency, neonatal, neurological distress and, 172
Supportive care of neonatal acute leukemia patients, 282
Surfactant protein B (SPB) deficiency, lung-directed fetal gene therapy for, 526-527
Surgery
of neonatal cystic hygroma, 351-352
see also Fetal surgery *and specific conditions*
Susceptibility of children and neonates to fasting adaptation, 133-134
Sympathetic nervous system model of preeclampsia, 9
Syndromic associations
with cystic hygroma, 345
see also Syndromic associations with neonatal WT
Syndromic associations with neonatal WT, 313-314
BWS and PS as, 315
DDS as, 314-315
FWT and WAGR as, 314
Simpson-Golabi-Behmel syndrome as, 315-315
Sotos syndrome as, 316
TA (tufted angioma; angioblastoma), neonatal, 336
Table salt (sodium chloride; table salt), preeclampsia prevention with diet low in, 62
Tandem mass spectrometry, *see* Electrospray tandem mass spectrometry, neonatal screening with, for inborn errors of metabolism
Target cells, fetal, in maternal circulation, selection of, 393-395
Team of multidisciplinary specialists in CFDT, 536
Temporary brittle bone disease (TBBD), perinatal, 174-182
characteristics of, 177-178
differential diagnosis between child abuse and, 178-181
personal experience with, 175-177
Teratoma
fetal cervical, airway obstruction due to, 498
sacrococcygeal, open fetal surgery for, 457-459
Tetrahydrobiopterin, defects in metabolism of, 195-200
diagnosis and treatment of, 198-200
presentation and clinical features of, 195-197
TFP (trifunctional protein) deficiency, fetal, FAO disorders and, 103-105
Therapy and management
fetal, *see* Fetal cell therapy; Fetal surgery; Therapy and management of fetal and neonatal cystic hygroma *and specific conditions*
of HLH, 327
of LCH, 324-325
of neonatal bacterial meningitis, 219-220, 223-225
of neonatal brain tumors, 294-295
of neonatal leukemia, 282
of neonatal neuroblastoma, 270-271
palliative care of neonates, decision to provide, 240
of preeclampsia, *see* Eclamptic seizures, prevention of; Prevention of preeclampsia; Severe preeclampsia, management of
of soft tissue sarcomas of infancy, 307
see also Dietary therapy; Neuroprotective therapy after severe birth asphyxia; Prevention; Therapy and management of fetal and neonatal cystic hygroma; Therapy and management of inborn errors of metabolism; Therapy and management of neonatal vascular tumors
Therapy and management of fetal and neonatal cystic hygroma, 349-353
neonatal considerations in, 351
nonsurgical, 352-353
prenatal considerations in, 349-351
surgical, 351-352
Therapy and management of inborn errors of metabolism
of AMD, 128
of branching enzyme deficiency, 133
of carnitine deficiency, 159-160
of debrancher deficiency, 131
follow-up on, role of electrospray MS/MS in, 187-189

of metabolic myopathies due to FAO disorders, 141-143
of monoamine neurotransmission disorders, 198-201
of PBK deficiency, 129
of PFK deficiency, 132
of phosphorylase deficiency, 130
Therapy and management of neonatal vascular tumors, 335-337
hemangioma, 335-336
KHE and TA, 336
of pyogenic granuloma, angiosarcoma, eccrine nevus, 337
Timing
of fetal surgery for MMC, 464-465
of first trimester CVS, 403-405
Tissue(s)
FAO-dependent, FAO disorders and, 134
sampling of fetal, with embryofetoscopy, 428-429
tissue-specific differences in fatty acid utilization, 101
Tissue carnitine, alterations in, and neonatal metabolic myopathies due to FAO disorders, 134-135
TMD (transient myeloproliferative disorder), differential diagnosis between neonatal acute leukemia and, 281-282
TNF-α (tumor necrosis factor-α) in inflammation triggered by neonatal GBS meningitis, 251-256
Total carnitine in neonatal metabolic myopathies due to FAO disorders, 139
Transfer ribonucleic acid (tRNA), maternally transmitted point mutations in, respiratory chain disorders and, 115, 121
Transfusion syndrome, twin-twin, fetoscopy for, 478-481
Transient myeloproliferative disorder (TMD), differential diagnosis between neonatal acute leukemia and, 281-282
Transient tyrosinemia, neonatal, neurological distress and, 172
Translocase defects, neonatal mitochondrial disorders and, 115, 119
Translucency, nuchal, *see* Nuchal translucency, fetal structural anomalies and
Transplantation, *see* Hematopoietic stem cell transplantation, fetal
TRAP (twin reversed arterial perfusion) sequence, fetoscopy for, 476-478
Treatment, *see* Therapy and management
Trifunctional protein (TFP) deficiency, fetal, pediatric FAO disorders and, 103-105
Triglyceride(s), as core of human MFG, 245-247
Triglyceride oil, medium-chain, in therapy of FAO disorders, 142
Trisomy 18 (Edwards syndrome), first trimester screening for, with serum biochemical markers, 364
Trisomy 21, *see* Down's syndrome
tRNA (transfer ribonucleic acid), maternally transmitted point mutations in, respiratory chain disorders and, 115, 121
TTTS (twin-twin transfusion syndrome), fetoscopy for, 478-481
Tufted angioma (TA; angioblastoma), neonatal, 336
Tumor(s), *see* Neonatal tumors *and specific tumors*
Tumor necrosis factor-α (TNF-α) in inflammation triggered by neonatal GBS meningitis, 251-256
Twin(s)
studies of neonatal leukemia in, 275-276
see also Monochorionic twin pregnancy, fetoscopy for complications of
Twin reversed arterial perfusion (TRAP) sequence, fetoscopy for, 476-478
Twin-twin transfusion syndrome (TTTS), fetoscopy for, 478-481
Tx (transplantation), *see* Hematopoietic stem cell transplantation, fetal
Tyrosine hydroxylase deficiency
diagnosis and therapy of, 200
and monoamine biosynthesis, 197
Tyrosinemia
hereditary tyrosinemia type I and transient neonatal, 172
liver-directed fetal gene therapy for hypertyrosinemia type I, 530

Ultrafast magnetic resonance imaging (MRI), fetal anomalies diagnosed with, 437-447
abdominal, 444-446
central nervous system anomalies, 438-441
chest anomalies, 442-444
neck masses, 441-442
Ultrasound, *see* Doppler ultrasound of preeclampsia; Fetal ultrasound *entries beginning with terms*: Nuchal translucency sonography *and specific conditions*
Uncommon soft tissue sarcomas of infancy, 304-307
Uncooked corn starch, as therapy of FAO disorders, 142
Unexpected death, sudden and, postmortem pediatric diagnosis of FAO disorders in, 204-210
Unexplained masses and nodules in neonatal neuroblastoma, 266-267
Unselected populations, nuchal translucency sonography in detection of aneuploidy in, 372-374
Upper extremity paresis, and neonatal neuroblastoma 265-266
Urethral valves, posterior, fetoscopic cystoscopic ablation of, in obstructive uropathy, 491
Uropathy, *see* Obstructive uropathy, fetal surgery for
Uteroplacental blood flow, velocity of, in preeclampsia, Doppler ultrasound measurement of, 53-54
Uteroplacental circulation, 24-26
in normal pregnancy, 24-25
in preeclampsia, 26
Uteroplacental ischemia in preeclampsia, 2-5, 15, 27

Vascular malformations, neonatal, 334, 337
Vascular reactivity in preeclampsia, 34-44
  effects of plasma from preeclamptic patient on, 39-41
  endothelium and, *see* Endothelium in preeclampsia
  of isolated omental artery, 38-39
  structural and mechanical changes in vessels and, 41
Vascular tumors in infancy, 332-340
  future research on, 337-338
  incidence of, 332-334
  pathogenesis of, 332, 334
  types of, 334-337
Vasoconstriction in preeclampsia, 26
Vasodilatory state in normal pregnancy, 24
Vectors used in fetal gene therapy, 525-526
Vesicoamniotic shunting for fetal obstructive uropathy, 490-491
Villus sampling, *see* Chorionic villus sampling, first trimester
Vitamin B_2 (riboflavin) in therapy of FAO disorders, 142

WAGR (Wilms' tumor-aniridia-genitourinary malformation and mental retardation) with WT, 314
Wilms' tumor, fetal and neonatal, 310-318
  congenital, 313
  genetics of, 312-313
  MN and, 311-312
  NR and, 312
  screening for, 316
  syndromic associations with, *see* Syndromic associations with neonatal WT
Wilms' tumor-aniridia-genitourinary malformation and mental retardation (WAGR), 314

Xanthogranuloma, juvenile, in infancy, 328

Zinc supplementation, prevention of preeclampsia with, 61